Brookdale Senior Living (BKD) Q4 2025 earnings summary
Event summary combining transcript, slides, and related documents.
Q4 2025 earnings summary
10 Apr, 2026Executive summary
Achieved a 19% increase in Adjusted EBITDA to $458 million for 2025, marking the fourth consecutive year of double-digit growth and surpassing guidance midpoint.
Fourth quarter 2025 weighted average occupancy reached 82.5%, the highest since Q1 2020, with same-community occupancy at 83.5% and a 310 bps year-over-year increase.
Adjusted Free Cash Flow turned positive for the first time since 2020, reaching $23 million for 2025.
Portfolio optimization included significant lease terminations and planned sale of 29 owned communities in 2026, expected to generate $200 million in proceeds.
Strategic priorities focus on operational excellence, real estate optimization, capital reinvestment, leverage reduction, and quality elevation for residents and associates.
Financial highlights
Adjusted EBITDA grew 19% year-over-year to $458 million in 2025, with Q4 Adjusted EBITDA up 7% to $106 million.
Resident fees increased 2.4% to $3.04 billion for 2025, driven by 5.7% RevPAR growth, offset by a 3.2% decline in average available units.
Consolidated weighted average occupancy for 2025 was 80.9%.
Q4 2025 resident fees decreased 4.0% year-over-year to $714.5 million, mainly due to community dispositions.
Full year 2025 net loss was $263 million, with Q4 net loss narrowing to $40 million.
Outlook and guidance
2026 guidance: 8–9% RevPAR growth and Adjusted EBITDA of $502–$516 million.
Expect mid-teen Adjusted EBITDA growth through 2028, targeting leverage below 6x by end of 2028.
Non-development capital investment projected at $175 million–$195 million for 2026.
General and administrative expense estimated at $162 million for 2026.
Average occupancy is expected to exceed 83% in 2026, benefiting from favorable supply-demand dynamics.
Latest events from Brookdale Senior Living
- Operational focus, targeted CapEx, and market-driven M&A support growth amid strong demand.BKD
Barclays 28th Annual Global Healthcare Conference10 Mar 2026 - Q2 saw 20% Adjusted EBITDA growth, higher occupancy, but a wider net loss on higher costs.BKD
Q2 20241 Feb 2026 - 2026 targets $502–$516M Adjusted EBITDA and 8–9% RevPAR growth, led by operational transformation.BKD
Investor Day 202630 Jan 2026 - Q3 2024 delivered 15% EBITDA growth, higher occupancy, and $610M in acquisitions pending.BKD
Q3 202415 Jan 2026 - Strategic acquisitions, strong occupancy, and HealthPlus expansion drive positive 2025 outlook.BKD
Stephens 26th Annual Investment Conference | NASH202413 Jan 2026 - Accelerating occupancy, strong cash flow, and innovation position for sustained growth.BKD
Barclays 27th Annual Global Healthcare Conference26 Dec 2025 - 2024 results beat guidance; 2025 targets 11%-15% EBITDA growth and positive cash flow.BKD
Q4 202415 Dec 2025 - Contested director election, performance-based pay, and auditor ratification headline the 2025 proxy.BKD
Proxy Filing1 Dec 2025 - Ortelius seeks to overhaul board leadership to address underperformance and drive value creation.BKD
Proxy Filing1 Dec 2025